3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
28
Neoplasm Metastasis
9
Neoplasms
8
Brain Neoplasms
5
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Glioma
3
Endometrial Neoplasms
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Liposarcoma
2
Head and Neck Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Interventions
capivasertib
2
Fulvestrant
2
ribociclib
1
palbociclib
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
abemaciclib
×
90 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled